Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

|Articles|May 30, 2019

VISUMAX 800 - Why speed matters

Author(s)Detlev R.H. Breyer, MD

DOWNLOAD THE CASE STUDY

Newsletter

Don’t miss out—get OT Europe updates delivered straight to your inbox.

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

MacTel Decoded: Rethinking Conventional Approaches With Novel Neuroprotective Strategies

Charles C. Wykoff MD, PhD; Diana V. Do, MD; Dante Pieramici, MD, FASRS; Jed H. Assam, MD, MS

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Treatment Optimization in the Evolving Anti-VEGF Era

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

Mary Qiu, MD; Paul Singh, MD; Danica J. Marrelli, OD, FAAO

(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Rahul Tonk, MD; Jade Coats, OD, FAAO; Aaleya Koreishi, MD; Zeba Syed, MD

(COPE Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

(COPE Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

John Kitchens, MD

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

Geeta Lalwani, MD; Alla Goldberg, MD; Elite Bor-Shavit, MD

Trending on Eye Care Network - Ophthalmology Times

FDA requires NAION warning across the GLP-1 receptor agonist class

Anti-VEGF switches for persistent fluid: A review of 3 clinical cases

City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease

Inflammasome inhibition with K8 in geographic atrophy: A Q&A

Tenpoint Therapeutics opens telehealth access to Yuvezzi for adults with presbyopia